公开(公告)号：EP4327823A1

公开(公告)日：2024-02-28

申请号：EP22791768.9

申请日：2022-04-21

申请人： Astellas Pharma Inc. ,  National Cancer Center

发明人： TENDA, Yoshiyuki ,  YURI, Masatoshi ,  YAGI, Shigenori ,  SATAKE, Yoshiki ,  HIRAYAMA, Kazunori ,  SHIRAI, Hiroki ,  SASAKI, Hiroki ,  CHIWAKI, Fumiko ,  KOMATSU, Masayuki

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/46 ,  C12N5/10 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N15/13 ,  C12N15/62 ,  C12N15/63 ,  C12P21/08

摘要： An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer.
An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD 137 antibody binding to CD137 had agonistic activity for CD 137, promoted production of interferon y by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer.

公开(公告)号：EP3650470A1

公开(公告)日：2020-05-13

申请号：EP18827622.4

申请日：2018-07-06

申请人： Astellas Pharma Inc.

发明人： DOIHARA, Hitoshi ,  HIRAYAMA, Kazunori ,  SHIRAI, Hiroki

IPC分类号： C07K16/30 ,  C07K1/13 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/13 ,  C12N15/63 ,  C12P21/08 ,  G01N33/574

摘要： Provided are an anti-human CEACAM5 antibody Fab fragment expected to be useful in the diagnosis of a cancer, particularly, the diagnosis of colorectal cancer, breast cancer, lung cancer, thyroid gland cancer or a cancer resulting from the metastasis thereof, and a diagnosis approach using a conjugate comprising the Fab fragment. The present invention provides an anti-human CEACAM5 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 121 of SEQ ID NO: 2, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 112 of SEQ ID NO: 4, and a conjugate comprising the Fab fragment.

公开(公告)号：EP3909606A1

公开(公告)日：2021-11-17

申请号：EP20737956.1

申请日：2020-01-06

申请人： Astellas Pharma Inc.

发明人： AKAIWA, Michinori ,  ISHIDA, Junya ,  TOYA, Hiroki ,  SHIRAISHI, Nobuyuki ,  ASANO, Toru ,  YOSHIKAWA, TOMOAKI ,  SANO, Yorikata ,  DOIHARA, Hitoshi ,  SHIRAI, Hiroki ,  HIRAYAMA, Kazunori

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/30 ,  A61K47/52 ,  A61K47/54 ,  A61K47/65 ,  A61K47/68 ,  A61K49/16 ,  C12N15/13 ,  A61K51/10 ,  G01N33/53 ,  G01N33/574

摘要： Provided is a conjugate comprising a ligand, a spacer, and a peptide linker useful for an in-vivo diagnostic drug and internal radiation therapy, using an anti-human CEACAM5 antibody Fab fragment whose binding activity is not attenuated even by labeling with a metal, a fluorescent dye, or the like. A conjugate comprising an anti-human CEACAM5 antibody Fab fragment and a ligand, the fragment comprising a heavy chain fragment including a heavy chain variable region consisting of a specific amino acid sequence and a light chain including a light chain variable region consisting of a specific amino acid sequence, or a conjugate comprising a ligand, a spacer, and a peptide linker, wherein the binding activity thereof is not attenuated even by labeling with a metal, a fluorescent dye, or the like, can be used as a diagnostic composition and/or a pharmaceutical composition.

公开(公告)号：EP3795590A1

公开(公告)日：2021-03-24

申请号：EP19804452.1

申请日：2019-05-17

申请人： Astellas Pharma Inc.

发明人： ASANO, Toru ,  SANO, Yorikata ,  MORINAKA, Akifumi ,  SHIRAI, Hiroki ,  HIRAYAMA, Kazunori ,  AKAIWA, Michinori ,  YAMADA, Hiroyoshi ,  SHIRAISHI, Nobuyuki

IPC分类号： C07K16/28 ,  A61K31/16 ,  A61K31/395 ,  A61K39/395 ,  A61K47/65 ,  A61K47/68 ,  A61K51/10 ,  A61P1/00 ,  A61P1/04 ,  A61P1/18 ,  A61P5/14 ,  A61P11/00 ,  A61P13/10 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P35/00 ,  C12N15/13 ,  A61K103/00

摘要： Provided are a conjugate comprising an anti-human MUC1 antibody Fab fragment and a peptide linker and/or a ligand, a composition for diagnosis and/or a pharmaceutical composition comprising the conjugate, a method for diagnosing and/or treating a cancer using the conjugate, and the like. In the conjugate used, the anti-human MUC1 antibody Fab fragment is bound to the ligand via the peptide linker or the like.